Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

Favorable regulatory moves for a new drug application, blowout earnings and promising preclinical data triggered a flurry of ...